Riskpilot← Back to searchSign inGet full accessSVAR Life Science AB
ABActiveOrg 5565640645Lundavägen 151Manufacture of other chemical products n.e.c. · NACE 2059Est. 199889 employees
Revenue 2024
SEK 224,4M
+8% vs 2023
EBITDA margin
16.0%
+21% vs 2023
Equity ratio
77.8%
Financial strength
Net profit 2024
SEK 34,8M
-48% vs 2023
| Revenue | SEK 224,4M | +8% |
| EBITDA | SEK 35,9M | +21% |
| Net profit | SEK 34,8M | -48% |
| Total assets | SEK 297,1M | +20% |
| Equity | SEK 231,1M | +18% |
| Employees | 89 | — |
Legal name
SVAR Life Science AB
Org number
5565640645
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
15 december 1998
Share capital
SEK 293 000
Employees
89 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Long, Ronald Eric Firman tecknas två i förening av ledamöterna suppleanten externa firmatecknarna Thjømøe, Anne Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att äga och förvalta bolag inom den farmaceutiska branschen samt att tillverka, utveckla och idka handel med medicinska, diagnostiska, farmaceutiska och kemisk-tekniska produkter, att förvärva och upplåta licenser och agenturer för sådana produkter och motsvarande rättigheter, att idka därmed förenlig verksamhet sam att idka finansiell verksamhet. Bolaget skall dock ej driva sådan verksamhet som avses i lag 2004:297 om bank- och finansierings- rörelse.
Address
Lundavägen 151
Phone
+4640537600
Email
info@eurodiagnostica.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 130 129 | 142 286 | 184 667 | 208 629 | 224 381 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 12 746 | 11 941 | 48 055 | 29 546 | 35 894 |
| Depreciation & amort. | −4 282 | −4 468 | −4 846 | −5 327 | −2 570 |
| EBIT | 8 464 | 7 473 | 43 209 | 24 219 | 33 324 |
| Net financials | −4 690 | −1 802 | −8 453 | −14 653 | 6 246 |
| Profit before tax | 7 703 | −22 431 | 1 275 | 75 145 | 44 199 |
| Tax | 14 330 | 5 665 | −11 204 | −8 512 | −9 384 |
| Net profit | 22 033 | −16 766 | −9 929 | 66 633 | 34 815 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 224 000 | 244 568 | 240 251 | 247 722 | 297 106 |
| Equity | 153 594 | 139 624 | 129 695 | 196 328 | 231 143 |
| Long-term debt | 2 670 | 0 | 0 | 0 | 0 |
| Short-term debt | 67 736 | 104 944 | 110 556 | 51 394 | 65 963 |
| Total debt | 70 406 | 104 944 | 110 556 | 51 394 | 65 963 |
EBITDA margin
16.0%
This company
15.8%
Market median
+1% vs market
20202024
Equity ratio
77.8%
This company
38.2%
Market median
+104% vs market
20202024
Return on equity
15.1%
This company
18.4%
Market median
+18% vs market
20202024
Net profit margin
15.5%
This company
8.1%
Market median
+91% vs market
20202024
Asset turnover
0.76×
This company
1.12×
Market median
-32% vs market
20202024
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
AT Chief Executive Officer | Chief Executive Officer | 2022 |
FI External Signatory | External Signatory | 2025 |
AC External Signatory | External Signatory | 2022 |
EM Chief Auditor | Chief Auditor | 2024 |
| Former (3) | ||
AS External Signatory | External Signatory | 2022 – 2025 |
SJ Chief Auditor | Chief Auditor | 2020 – 2024 |
CJ Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2020 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DRAUPNIR HOLDING B.V
SVAR Life Science AB (this company)Biomonitor ApsSvar Life Science SasCalpro ASSvar Life Science IncBIOMONITOR APSSVAR LIFE SCIENCE SASSVAR LIFE SCIENCE INCBoard members of SVAR Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Thjømøe | Chief Executive Officer | 0 companies |
| Fanny Ingeborg Arvedson | External Signatory | 0 companies |
| Anna Sofi Karin Pramhed | External Signatory | 0 companies |
| Anna Cecilia Björklund | External Signatory | 0 companies |
| Eva Mari Yng | Chief Auditor | 0 companies |
| Sven Jakob Tenselius | Chief Auditor | 0 companies |
| Carl Jörgen Dahlström | Chief Executive Officer | 0 companies |
| Lisbeth Astrid Anette Witt | Board of Directors | 0 companies |
| Ronald Eric Long | Chairman | 0 companies |
| Erik Henricus Schropp | Board of Directors | 0 companies |
| Eva Camilla Duborn | Deputy Board Member | 0 companies |